Millar Kerri-Ann
Known title: CHIEF FINANCIAL OFFICERCIK: 0001739126
Associated companies
Transaction History
| CUE | ▼ Sell | Tax Withholding | 2,828 | $9K | 8/22/2022 | View on chart |
| CUE | ▲ Buy | Option Exercise | 6,667 | — | 8/21/2022 | View on chart |
| CUE | ▲ Buy | Option Exercise | 1,251 | $9K | 10/1/2021 | View on chart |
| CUE | ▼ Sell | Open Market | 1,251 | $18K | 10/1/2021 | View on chart |
| CUE | ▲ Buy | Option Exercise | 6,667 | $0 | 8/23/2021 | View on chart |
| CUE | ▼ Sell | Tax Withholding | 1,961 | $0 | 8/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.